Establishment of Camden RAD, LLC, a company devoted to stem cell research and development.
Camden RAD, LLC is rebranded as Stem Cell Innovations, and a new company is established, based on blockchain technology.
Advanced research begins to determine market and development opportunities.
Attended Token 2049 conference in Hong Kong.
Attended Stem Cell Summit at the University of California in Los Angeles (UCLA).
Attended CBC conference in San Francisco, CA.
Attended ICO20 Summit in Santa Monica, CA.
Integration of smart contract technology is established.
Company headquarters incorporated in Gibraltar, GB.
Strategic efforts toward development begins.
Interviews with potential medical participants take place.
Whitelist is scheduled to go live.
Token Sale starts.
Token Sale ends and min max caps are assessed.
Distribution of Tokens to participants through ERC20 will commence.
SCI will begin final testing and reporting based on blockchain technology being used.
Creation of a non-identical patient identification factor on Passive Blockchain Node will be initialized.
Demo testing for SCI Application v 1.0 will begin.
Release of the SCI Application v1.1
Enrollment begins for doctors, patients, and stem cell laboratories in the United States
Release of Market Surveillance strategy for further growth
Release SCI Application v2.0
Enrollment begins for professionals, patients, and stem cell laboratories in Middle East and across North Africa.
Announcement of first SCI Lab location and franchise expansion plan.
Announcement of clinical development and research strategy in the stem cell field.
Public announcement regarding SCI achievements to date.
First ever online synthetic stem cell purchase through the SCI Application. Release SCI Application v3.0, fully functional platform for professionals and patients.
Stem Cell Lab Evaluation report per first year of operation and development.
Release SCI earnings and financials report.
Release results of SCI's stem cell research and development to date.
Expansion of SCI stem cell labs and clinics in China, Japan, South Korea, and India.
Begin charging membership fees (payable in Stem Cell Innovations tokens) for professional-facing portion of SCI application.
Begin second phase of SCI stem cell research and development.
Release SCI Application v3.5, including professional-facing component to help practitioners become more involved in the stem cell research space and contribute to the network.
Expansion and acquisition of SCI stem cell labs and clinics in Europe.
Release SCI earnings and financials report for second year operation and development.
Release public update on SCI stem cell research and development.
Stem Cell Lab Evaluation report for second year.
Release SCI Application v4.0 including:
A new platform for medical students, universities, and hospitals to engage with the SCI Application.
Fully Functional EMR Worldwide Enforcing HIPPA and expanding of synthetic stem cell delivery to Latin America.